| mRNA vaccine–induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer G Cafri, JJ Gartner, T Zaks, K Hopson, N Levin, BC Paria, MR Parkhurst, ... The Journal of clinical investigation 130 (11), 5976-5988, 2020 | 269 | 2020 |
| Proliferating cell nuclear antigen is a novel inhibitory ligand for the natural cytotoxicity receptor NKp44 B Rosental, M Brusilovsky, U Hadad, D Oz, MY Appel, F Afergan, ... The Journal of Immunology 187 (11), 5693-5702, 2011 | 249 | 2011 |
| Unique neoantigens arise from somatic mutations in patients with gastrointestinal cancers MR Parkhurst, PF Robbins, E Tran, TD Prickett, JJ Gartner, L Jia, G Ivey, ... Cancer discovery 9 (8), 1022-1035, 2019 | 204 | 2019 |
| Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy R Yossef, E Tran, DC Deniger, A Gros, A Pasetto, MR Parkhurst, ... JCI insight 3 (19), 2018 | 202 | 2018 |
| Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers FJ Lowery, S Krishna, R Yossef, NB Parikh, PD Chatani, N Zacharakis, ... Science 375 (6583), 877-884, 2022 | 199 | 2022 |
| T-cell responses to TP53 "hotspot" mutations and unique neoantigens expressed by human ovarian cancers RSA Deniger DC, Pasetto A, Robbins PF, Gartner JJ, Prickett TD, Paria BC ... Clin Cancer Res., 2018 | 147 | 2018 |
| Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients G Cafri, R Yossef, A Pasetto, DC Deniger, YC Lu, M Parkhurst, JJ Gartner, ... Nature communications 10 (1), 449, 2019 | 133 | 2019 |
| Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes A Gros, E Tran, MR Parkhurst, S Ilyas, A Pasetto, EM Groh, PF Robbins, ... The Journal of clinical investigation 129 (11), 4992-5004, 2019 | 126 | 2019 |
| Antigen experienced T cells from peripheral blood recognize p53 neoantigens P Malekzadeh, R Yossef, G Cafri, BC Paria, FJ Lowery, M Jafferji, ... Clinical Cancer Research 26 (6), 1267-1276, 2020 | 91 | 2020 |
| Serum apolipoproteins CI and C-III are reduced in stomach cancer patients: results from MALDI-based peptidome and immuno-based clinical assays M Cohen, R Yossef, T Erez, A Kugel, M Welt, MM Karpasas, J Bones, ... PloS one 6 (1), e14540, 2011 | 61 | 2011 |
| The natural cytotoxicity receptor 1 contribution to early clearance of Streptococcus pneumoniae and to natural killer-macrophage cross talk S Elhaik-Goldman, D Kafka, R Yossef, U Hadad, M Elkabets, ... PloS one 6 (8), e23472, 2011 | 52 | 2011 |
| The effect of chemotherapy/radiotherapy on cancerous pattern recognition by NK cells B Rosental, M Y Appel, R Yossef, U Hadad, M Brusilovsky, A Porgador Current medicinal chemistry 19 (12), 1780-1791, 2012 | 39 | 2012 |
| Array-based disease diagnostics using lipid/polydiacetylene vesicles encapsulated in a sol–gel matrix S Kolusheva, R Yossef, A Kugel, M Katz, R Volinsky, M Welt, U Hadad, ... Analytical chemistry 84 (14), 5925-5931, 2012 | 38 | 2012 |
| Regulation of natural cytotoxicity receptors by heparan sulfate proteoglycans in ‐cis: A lesson from NKp44 M Brusilovsky, O Radinsky, L Cohen, R Yossef, A Shemesh, A Braiman, ... European journal of immunology 45 (4), 1180-1191, 2015 | 35 | 2015 |
| α1‐Antitrypsin modifies general natural killer cell interactions with dendritic cells and specific interactions with islet β‐cells in favour of protection from autoimmune … O Guttman, R Yossef, G Freixo‐Lima, P Rider, A Porgador, EC Lewis Immunology 144 (3), 530-539, 2015 | 31 | 2015 |
| Dimerization of NKp46 receptor is essential for NKp46-mediated lysis: characterization of the dimerization site by epitope mapping M Jaron-Mendelson, R Yossef, MY Appel, A Zilka, U Hadad, F Afergan, ... The Journal of Immunology 188 (12), 6165-6174, 2012 | 31 | 2012 |
| Targeting natural killer cell reactivity by employing antibody to NKp46: implications for type 1 diabetes R Yossef, C Gur, A Shemesh, O Guttman, U Hadad, S Nedvetzki, A Miletić, ... PloS one 10 (2), e0118936, 2015 | 30 | 2015 |
| Inhibition of the NKp44-PCNA immune checkpoint using a mAb to PCNA K Kundu, S Ghosh, R Sarkar, A Edri, M Brusilovsky, O Gershoni-Yahalom, ... Cancer immunology research 7 (7), 1120-1134, 2019 | 27 | 2019 |
| NKp44-derived peptide binds proliferating cell nuclear antigen and mediates tumor cell death A Shemesh, K Kundu, R Peleg, R Yossef, I Kaplanov, S Ghosh, ... Frontiers in immunology 9, 1114, 2018 | 27 | 2018 |
| Identification and Validation of T-cell Receptors Targeting RAS Hotspot Mutations in Human Cancers for Use in Cell-based Immunotherapy N Levin, BC Paria, NR Vale, R Yossef, FJ Lowery, MR Parkhurst, Z Yu, ... Clinical Cancer Research 27 (18), 5084-5095, 2021 | 26 | 2021 |
